Pfizer expands COVID-19 vaccine tests in children under 12, to enrol over 4,500 kids

"This is the next step allowing us to gather data to understand the safety and immunogenicity of the vaccine," Pfizer said.

New Delhi: Pfizer on Tuesday (June 8, 2021) announced that it is expanding testing of its COVID-19 vaccine in kids under 12 years of age. Pfizer said that they are beginning Phase 2/3 part of their continuous study of their COVID-19 vaccine in healthy children.  "This is the next step allowing us to gather data to understand the safety and immunogenicity of the vaccine in this group aged 5–11 years," Pfizer said. The American company said that the Phase 1/2/3 dose-escalation study in children will evaluate the tolerability of the Pfizer-BioNTech COVID-19 vaccine on a two-dose schedule (approximately 21 days apart) in three age groups: